Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PKBO

Peak Bio (PKBO) Stock Price, News & Analysis

Peak Bio logo

About Peak Bio Stock (NASDAQ:PKBO)

Advanced Chart

Key Stats

Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.11
52-Week Range
$0.00
$0.26
Volume
66,140 shs
Average Volume
8,940 shs
Market Capitalization
$520,312.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.

Receive PKBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Peak Bio and its competitors with MarketBeat's FREE daily newsletter.

PKBO Stock News Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Peak Bio Inc (PKBO)
Peak Bio, Inc. (PKBO)
What Peak 65 Means for My Gen X Clients
AKARI THER.ADR/2000 -,01 (CLA.MU)
See More Headlines

PKBO Stock Analysis - Frequently Asked Questions

Peak Bio, Inc. (NASDAQ:PKBO) released its earnings results on Tuesday, November, 12th. The company reported $0.06 earnings per share for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Peak Bio investors own include Check-Cap (CHEK), Pulmonx (LUNG), Minerva Neurosciences (NERV), Catalyst Biosciences (CBIO), Adicet Bio (ACET), Absci (ABSI) and Aeglea BioTherapeutics (AGLE).

Company Calendar

Last Earnings
11/12/2024
Today
4/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PKBO
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-12,830,000.00
Pretax Margin
-4,433.33%

Debt

Sales & Book Value

Annual Sales
$370,000.00
Price / Cash Flow
N/A
Book Value
($0.90) per share
Price / Book
-0.03

Miscellaneous

Free Float
18,523,000
Market Cap
$520,312.50
Optionable
Not Optionable
Beta
1.75
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:PKBO) was last updated on 4/29/2025 by MarketBeat.com Staff
From Our Partners